EyePoint Pharmaceuticals
在场
高管
查看带有其 22 名主要高管的组织结构图
EyePoint Pharmaceuticals 搜索最多的简介
- Jay Duker, President and Chief Executive Officer
- Wendy DiCicco, Director
- Nancy Lurker, Executive Vice Chairman of the Board
高管在EyePoint Pharmaceuticals变化
- Fred Hassan已作为Director加入公司 (新闻发布的2024九月5号).
- Ramiro Ribeiro已作为Chief Medical Officer加入公司 (新闻发布的2024三月5号).
- Dario Paggiarino, Senior Vice President & Chief Medical Officer, 已经离开公司 (新闻发布的2024三月5号).
创建提醒
跟踪 EyePoint Pharmaceuticals 的高管变动
医疗设备
EyePoint Pharmaceuticals 拥有 992 家竞争者，其中包括 Philips (荷兰)、Medtronic (爱尔兰岛) 和 Thermo Fisher Scientific (美国(美洲))。
Popular M&A news in 医疗设备
- Boston Scientific 已收购 Axonics Modulation Technologies (公布2024十一月18号).
- ShiraTronics 刚刚宣布为 66 筹款数百万美元。 (公布2024十月23号).
- Johnson & Johnson 已收购 V-Wave (公布2024十月9号).
医疗设备 行业的其他推荐联系人
消息
EyePoint Pharmaceuticals 的最新新闻稿
- VIDEO: EYP-1901 shows positive vision, treatment burden outcomes at 1 year
- EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | EyePoint Pharmaceuticals
- EyePoint Pharmaceuticals Reports Third Quarter 2024 Financial Results and Highlights Recent Corporate Developments | EyePoint Pharmaceuticals
- EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences | EyePoint Pharmaceuticals
- EyePoint Pharmaceuticals Announces Closing of Upsized Public Offering and Full Exercise of Option to Purchase Additional Shares | EyePoint Pharmaceuticals
- EyePoint Pharmaceuticals Announces Pricing of Upsized Public Offering | EyePoint Pharmaceuticals
- EyePoint Pharmaceuticals Announces Proposed Public Offering of Common Stock | EyePoint Pharmaceuticals
- EyePoint Pharmaceuticals Announces First Patient Dosed in Global Phase 3 LUGANO Clinical Trial of DURAVYU™ for the Treatment of Wet Age-Related Macular Degeneration | EyePoint Pharmaceuticals
- EyePoint Pharmaceuticals Announces Positive Interim 16-Week Data for Ongoing Phase 2 VERONA Clinical Trial of DURAVYU™ for Diabetic Macular Edema | EyePoint Pharmaceuticals
- EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | EyePoint Pharmaceuticals
- View more press releases Close
通过电子邮件
